Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05486312 · ClinicalTrials.gov registry record · NA
7-week Study With CT-155 in People With Schizophrenia
A NA study, sponsored by Click Therapeutics.
- Completed
- Registry status
- NA
- Development phase
- 72
- Enrollment target
NCT05486312: Completed NA study, sponsored by Click Therapeutics.
NCT05486312 is a NA study that has completed, run by Click Therapeutics. The registered enrollment target is 72 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05486312, a NA study, has completed, sponsored by Click Therapeutics.
- COMPLETED
- Registry status
- NA
- Development phase
- 72 participants
- Enrollment target
Study Summary
CT-155 is a novel prescription digital therapeutic (PDT) to treat schizophrenia
Primary Outcome
Participants ratings of Study App quality and satisfaction as measured by the Mobile App Rating Scale (MARS) at Week 7 The MARS is a validated 23-items rated on a 5-point anchored scale 1 being the lowest and 5 the highest
Interventions
- DEVICE CT-155 smartphone app
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2022-07-05 |
| Est. Completion | 2022-12-12 |
| Phase | NA |
What the finished NCT05486312 record still lists
NCT05486312 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 72 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 1 intervention - of which CT-155 smartphone app is the first listed.
NCT05486312 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05486312 about?
NCT05486312 is a clinical study titled "7-week Study With CT-155 in People With Schizophrenia". CT-155 is a novel prescription digital therapeutic (PDT) to treat schizophrenia
What is the current status of trial NCT05486312?
This trial is currently completed. It is a NA study. The enrollment target is 72 participants. The study started on 2022-07-05. Estimated completion is 2022-12-12.
What interventions are being tested in trial NCT05486312?
The interventions under investigation include: CT-155 smartphone app (DEVICE).
Who is sponsoring clinical trial NCT05486312?
This trial is sponsored by Click Therapeutics, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05486312's enrollment target sits among peer trials
72 1089th of 2000 higher than 899 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02359253 · 72 participants · NA
Robot Aided Rehabilitation - Intervention
- NCT02962661 · 72 participants · Phase 1
Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines
- NCT03113643 · 72 participants · Phase 1
SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- NCT03187535 · 72 participants · NA
Effect of TEAS on PONV After Spinal Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI